- Home
- Companies
- CIS Pharma AG
- Products
- CIS Pharma - Model CD 171 - ...
CIS Pharma - Model CD 171 -Antibody-Radionuclide Conjugate Targeting L1cam
Despite the advancements in therapies, cancer remains a significant health burden. Over 10 million cancer patients die every year. Especially aggressive forms of cancer with poor prognosis and high spread of metastasis remain an important challenge. CIS Pharma develops an antibody-radionuclide conjugate, ARC, a targeted treatment for cancer patients resistant to chemotherapy.
The antibody targets L1CAM (CD 171), a surface protein that is overexpressed in ovarian, colorectal, lung and many other types of cancer. The L1CAM surface protein was identified to be overexpressed in cancer-cells with high spread of metastasis and fast disease progression.
The therapeutic radionuclide Lutetium-177 is conjugated to the L1CAM antibody. Also, novel radionuclides are developed that exhibit greater potential in killing cancer cells compared to standard of care.
CIS Pharma’s payload technology enables the conjugation of radionuclides and/or cytotoxic payloads to the antibody. In-vivo data indicates a positive effect of the polymer carrier on conjugation of radionuclides to the antibody and on pharmacokinetics of the delivered radionuclide therapy. The polymer-based payload technology also serves as a dual-active carrier to conjugate compounds that exhibit synergies in killing cancer-cells, such as radionuclides and radiosensitizers.